Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Emerging Company Profile

Diagonal: Gluing receptor complexes back together

Newco uses AI/ML to find bispecific antibodies that can reassemble functional receptor complexes in the face of mutations

August 7, 2024 12:14 AM UTC

Launched in April, Diagonal is deploying its $128 million in series A funds to use its computational platform to efficiently mine combinations of agonist antibodies, seeking bispecific molecules capable of restoring the signaling of mutant receptor complexes.

Diagonal Therapeutics Inc. aims to treat diseases caused by mutations in receptors that disrupt binding to a partner receptor, reducing downstream signaling. The company’s bispecific antibodies bind two receptor subunits, acting as a glue to bring them together in a specific conformation that enables activation. The goal is a restoration of the receptor complex and its function...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article